Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells

Salort, José de; Sintes, Jordi; Llinàs, Laia; Matesanz-Isabel, Jessica; Engel, Pablo

doi:10.1016/j.imlet.2010.09.021

Cited by 63 publications

(59 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLAM family members are required for germinal center formation and for generation of humoral immune responses and memory B cells [32], [38], [39]. Studies of SLAMF1 expression in human B-cell subsets have demonstrated that its expression varies with stage of differentiation [38], [40]. SLAMF1 expression increases during B-cell development [40].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

et al. 2011

View full text Add to dashboard Cite

We developed and validated a two-gene signature that predicts prognosis in previously-untreated chronic lymphocytic leukemia (CLL) patients. Using a 65 sample training set, from a cohort of 131 patients, we identified the best clinical models to predict time-to-treatment (TTT) and overall survival (OS). To identify individual genes or combinations in the training set with expression related to prognosis, we cross-validated univariate and multivariate models to predict TTT. We identified four gene sets (5, 6, 12, or 13 genes) to construct multivariate prognostic models. By optimizing each gene set on the training set, we constructed 11 models to predict the time from diagnosis to treatment. Each model also predicted OS and added value to the best clinical models. To determine which contributed the most value when added to clinical variables, we applied the Akaike Information Criterion. Two genes were consistently retained in the models with clinical variables: SKI (v-SKI avian sarcoma viral oncogene homolog) and SLAMF1 (signaling lymphocytic activation molecule family member 1; CD150). We optimized a two-gene model and validated it on an independent test set of 66 samples. This two-gene model predicted prognosis better on the test set than any of the known predictors, including ZAP70 and serum β2-microglobulin.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Studies of SLAMF1 expression in human B-cell subsets have demonstrated that its expression varies with stage of differentiation [38], [40]. SLAMF1 expression increases during B-cell development [40]. However, SLAMF1 expression by memory B cells may vary depending upon the compartment studied.…”

Section: Discussionmentioning

confidence: 99%

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In humans, this molecule has been found to be widely distributed during B-cell development. Its expression appears to increase progressively during bone marrow maturation, and significant upregulation has been detected on the surface of tonsil plasma cells (PCs) [2]. Some interesting findings have shown that CD229 is constantly present on the surface of human bone marrow PCs, being expressed in myeloma cell lines, multiple myeloma (MM) and monoclonal gammopathies of uncertain significance (MGUS).…”

Section: Tablementioning

confidence: 99%

CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance

et al. 2015

View full text Add to dashboard Cite

“…Among the various membrane proteins already reported to identify stimulated IL-10 + B cells, we focused on assessing B cell expression of the integrin chains CD11c and b7, as well as members of the signaling lymphocyte activation molecule family, CD150 and CD229. Each of these surface markers has previously been reported to be expressed by human peripheral blood B cells (26), and the commercial availability of reagents directed against these molecules would enable other investigators to easily exploit their use for identification of human B-regs. First, we evaluated whether these markers could be used to define unique subsets of unstimulated B cells in PBMCs obtained from healthy donors.…”

Section: Differential Surface Expression Of Integrin Chains and Signamentioning

confidence: 99%

Human Regulatory B Cells Combine Phenotypic and Genetic Hallmarks with a Distinct Differentiation Fate

Lin

Cerny

Chua

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Regulatory B cells (B-reg) produce IL-10 and suppress inflammation in both mice and humans, but limited data on the phenotype and function of these cells have precluded detailed assessment of their contribution to host immunity. In this article, we report that human B-reg cannot be defined based on a phenotype composed of conventional B cell markers, and that IL-10 production can be elicited in both the CD27+ memory population and naive B cell subset after only a brief stimulation in vitro. We therefore sought to obtain a better definition of IL-10–producing human B-regs using a multiparameter analysis of B cell phenotype, function, and gene expression profile. Exposure to CpG and anti-Ig are the most potent stimuli for IL-10 secretion in human B cells, but microarray analysis revealed that human B cells cotreated with these reagents resulted in only ∼0.7% of genes being differentially expressed between IL-10+ and IL-10− cells. Instead, connectivity map analysis revealed that IL-10–secreting B cells are those undergoing specific differentiation toward a germinal center fate, and we identified a CD11c+ B cell subset that was not capable of producing IL-10 even under optimal conditions. Our findings will assist in the identification of a broader range of human pro–B-reg populations that may represent novel targets for immunotherapy.

show abstract

Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells

Cited by 63 publications

References 56 publications

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance

Human Regulatory B Cells Combine Phenotypic and Genetic Hallmarks with a Distinct Differentiation Fate

Contact Info

Product

Resources

About